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ABSTRACT
Background: Given the rising burden of hypertension in Africa, the Healthy Heart Africa program was
developed to improve access to quality hypertension care in the primary care setting. The Healthy Heart
Africa program provides a comprehensive, coordinated intervention directed at health care providers
(HCPs) and the general public.
Objective: The impact of Healthy Heart Africa on HCPs’ knowledge of hypertension and facility-level services
in Kenya was evaluated by a 12-month prospective study.
Methods: Intervention facilities were selected by stratified random sampling and matched to similar control
facilities. Intervention facilities received a hypertension treatment protocol, equipment, training and patient
education materials, and improved medical supply chain, whereas control facilities did not. HCPs
responsible for hypertension care were surveyed at baseline and 12 months later. Hypertension screening
and treatment data were abstracted from service delivery registers. A differences-in-differences analysis esti-
mated the impact of Healthy Heart Africa on HCPs’ knowledge, hypertension services, and the number of
patients diagnosed with and seeking treatment for hypertension.
Results: Sixty-six intervention and 66 control facilities were surveyed. Healthy Heart Africa improved HCPs’
knowledge of 5 hypertension risk factors and 5 methods for reducing/managing hypertension but not
hypertension consequences. At end line, more intervention than control facilities measured blood pressure
more than once during the same visit to diagnose hypertension, dedicated days to hypertension care, used
posters to increase hypertension awareness, and provided access to hypertension medications. The number
of patients diagnosed with hypertension and those seeking treatment for hypertension increased with
intervention, but the change was not significant relative to control subjects.
Conclusions: HCP-directed hypertension education and provision of basic resources positively influenced
hypertension care in Kenya in the first 12 months of implementation.
The growing burden of noncommunicable diseases,
including cardiovascular disease (CVD), is a major global
health problem. CVD is a leading cause of death worldwide
[1]. Hypertension alone, a major risk factor for CVD, is
responsible for approximately 9.4 million deaths annually
[2]. To combat the growing burden of CVD and hyperten-
sion, health care systems must be adequately educated and
equipped to provide preventative care and treatment op-
tions. Developing countries, which often have poor health
care infrastructure, face a double burden of disease, as the
rising rates of CVD and other noncommunicable diseases
occur along with existing communicable diseases (e.g., hu-
man immunodeficiency virus, malaria, and tuberculosis).
Kenya is one such country facing a growing prevalence
of CVD and hypertension. In Kenya, prevalence estimates
of hypertension range from 12.3% to 22.8% and CVD-
associated mortality from 6.1% to 8.0% [3-6]. Not sur-
prisingly, the high rates of hypertension and CVD are
observed in parallel with high prevalence rates of risk
factors for hypertension, including alcohol and tobacco use
and poor diet [7,8]. To further exacerbate the burden, the
overall awareness and control rate for hypertension remain
low [3,5,9]. The 2015 Kenya STEPwise survey found that
56% of Kenyans never had their blood pressure (BP) tested.
Among those diagnosed with hypertension, only 22.3%
were currently taking prescribed medication [5].
Multiple barriers exist to achieving adequate control of
hypertension in Kenya. Lack of confidence in health care
facilities because of various factors, including poor quality
of services, limited access to low-cost medications, and
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lack of functioning equipment, contribute to low utiliza-
tion and may affect hypertension control efforts [10-12].
Furthermore, anecdotal information suggests that diag-
nosis may occur after complications have developed, and
more severe illness puts additional pressure on secondary
health care systems. Providing greater access to BP
screening and hypertension services at the primary level
may improve the timely detection of elevated BP, hyper-
tension diagnosis, preventative care efforts, and associated
clinical outcomes.
Healthy Heart Africa (HHA) is an AstraZeneca-
sponsored program designed to improve access to quality
hypertension control in a primary care setting. Through
public-private collaborations, the HHA program aimed to
increase hypertension awareness and education among
health care providers (HCPs) and the general public; to
improve HCPs’ knowledge and skills for hypertension
screening and treatment; to create a protocol for hyper-
tension care; and to increase access to affordable hyper-
tension medications. Here, we report results from a
12-month prospective, controlled pilot study in Kenya
that evaluated the change in HCPs’ knowledge of hyper-
tension and facility-level hypertension screening and
treatment over the time of the HHA program.
MATERIALS AND METHODS
Overview of HHA in Kenya
The HHA program was initiated in March 2015 across 21
counties in Kenya, including Nairobi and the surrounding
areas and parts of Western Kenya (Online Fig. 1). HHA
partnered with an independent group of experts from
professional medical organizations (the Kenya Association
of Physicians, the Kenya Cardiac Society, and the Kenya
Renal Association) and academia to develop a uniform
protocol for screening and diagnosing hypertension, which
was endorsed by the Kenyan Ministry of Health before
implementation. The protocol includes a treatment algo-
rithm for hypertension and guidance regarding routine
evaluation (including BP measurement), potential drug
interactions, indications for immediate referrals, and
healthy lifestyle modifications (see Online Material 1 in the
Online Appendix, which describes the hypertension
treatment protocol).
HHA collaborated with 5 implementing partners (Ac-
ademic Model Providing Access to Healthcare, African
Medical and Research Foundation, Christian Health Asso-
ciation of Kenya, Jhpiego, and Population Services Kenya)
to integrate hypertension education and care into primary
health and outreach services provided at public, private,
and faith-based facilities. Each implementing partner
developed unique methods for increasing hypertension
awareness, education, and screening within the community
and among HCPs. A Kenyan pharmaceutical distributor,
the Mission for Essential Drugs and Supplies, ensured that
participating intervention facilities had free access to
AstraZeneca’s comprehensive hypertension medications.
Study design
The effect of HHA intervention on Kenyan HCPs’ knowl-
edge and practices of hypertension and facility-level hy-
pertension screening and treatment was evaluated as part
of a 12-month prospective analysis. Each implementation
partner provided a list of supported facilities from which
75 HHA intervention facilities were identified using a
randomized, multilevel clustered sampling approach. Each
selected intervention facility was then matched to a similar
control facility based on the implementing partner, county,
and facility type (e.g., district/subdistrict hospital, health
center, or dispensary/clinic). If these criteria could not be
satisfied, intervention facilities were matched to control
facilities from a neighboring county.
At program inception (in February 2015), a broad range
of trainers of trainers, including medical officers, diploma
clinicians (physician assistants), and nurses, from the
implementation partners were centrally trained by a physi-
cian (a consultant for HHA). The trainers of trainers from
each implementation partner then trained HCPs centrally
within their region. Toward the end of the first year, inter-
vention facilities, in particular those serving a high volume of
individuals, received additional training from trainers of
trainers. Participating intervention facilities also received
equipment (e.g., BP machines), training materials, the HHA
hypertension protocol, and educational materials (e.g.,
posters and brochures). Intervention facilities could also
procure HHA-recommended medications through Mission
for Essential Drugs and Supplies. HCPs received additional
training from the HHA/AstraZeneca Key Accounts team to
ensure that these medications were properly prescribed. In
this study, all health care facilities assigned intervention
received HHA program intervention within 7 to 8 months
following the baseline survey. Control facilities and associ-
ated HCPs did not receive these interventions.
To assess the effect of the HHA program, a facility
questionnaire was developed and pilot tested by Abt As-
sociates before fielding. Data collectors from Ipsos Syno-
vate Kenya (trained by Abt Associates and/or Ipsos project
leaders) administered the survey. Data were collected using
personal digital assistant phones.
The survey (see Online Material 2 in the Online
Appendix, which shows the facility questionnaire) was
administered shortly before the HHA program began in
February 2015 (referred to as baseline) and approximately
12 months later in March 2016 (referred to as end line). At
each participating facility, the survey was completed by the
facility manager and the HCP most likely to provide services
related to hypertension diagnosis, care, and treatment. The
facility manager was questioned regarding staffing, avail-
ability of equipment and supplies, and hypertension
screening data (based on medical records), whereas the
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HCPs were asked 17 questions pertaining to their knowl-
edge of hypertension (i.e., diagnosis, risk factors, conse-
quences, and treatment) and hypertension-related services
provided at the facility. The availability of hypertension
medication was recorded following visual confirmation or, if
not directly checked, based on facility manager report. Data
for the following outcomes were abstracted from service
delivery registers: available medications, number of adult
patients with hypertension seen at the facility within the
previous 3 months that either had hypertension or were
newly diagnosed with hypertension, and those who visited
the facility 1 time per month to check BP or receive hy-
pertension medication. BP screening and hypertension
diagnosis/treatment data (referred to as monitoring data)
were collected from participating intervention facilities and
as part of outreach BP screening campaigns conducted at
homes (door-to-door) and local gatherings (e.g., churches
and workplaces). Data collection at intervention facilities
was initiated after the completion of HCP training.
This study was reviewed and approved first by the Abt
Associates Internal Review Board, then by the Kenyatta
National Hospital and the University of Nairobi Ethics and
Research Committee (KNH/UON-ERC). Written informed
consent was obtained from all survey respondents prior to
completing the survey.
Statistical analysis
A differences-in-differences regression analysis was used to
assess treatment effect. By comparing the change in
outcomes over time among intervention facilities to that of
matched control facilities, the differences-in-differences
analysis minimized bias due to other factors that change
over the same time frame, allowing the effect of the HHA
intervention to be identified. Individual intervention facil-
ities were matched to individual control facilities based on
implementation partner, facility type (hospital, health
center, or dispensary/clinic), and county (taking care not to
match facilities that were too close in proximity to mini-
mize or avoid potential overlap in patient populations).
Perfect matches on all three dimensions were not always
possible. The analysis also controlled for urban versus rural
setting, facility medical staffing (the presence of a doctor, a
clinical officer, and/or a Kenyan registered nurse), facility
resources (e.g., working electricity and piped water), and,
for control facilities, the distance to its paired intervention
facility. The final analysis excluded facilities that had closed
or those unwilling to participate at end line. To maintain
balance between the treatment groups, any matched pair in
which one facility fell out of the sample or switched
treatment (e.g., the control facility received the interven-
tion, or the intervention facility did not) was excluded
unless the facilities could be matched with a different fa-
cility pair that had the same characteristics (with weights
updated accordingly).
At baseline, balance between the intervention and con-
trol groups was determined using a t test for bimodal vari-
ables and a chi-square test for outcomes with more than 2
possible values. Analysis conditioning, using the thresholds
Facilities Identified (N = 150)
Control (n = 75)
Baseline (n = 148)
Control (n = 73)
Endline (n = 132)
Control (n = 66)
Dropped because of missing
FIGURE 1. Facility attrition.
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of 3 and 5, was used to evaluate improvement in HCPs’
knowledge of hypertension risk factors and consequences
and methods for managing hypertension. The differences-
in-differences regressions were conducted using weighted
least squares. No adjustments were made for multiplicity.
RESULTS
Facilities characteristics and staffing
Of the 150 facilities originally planned for this analysis, 18
(9 from each arm) were excluded because of facility
closure, missing intervention/control pair, or unwillingness
to participate at end line (Fig. 1). The final analysis
included 66 intervention and 66 control facilities, con-
sisting of dispensaries/clinics, health centers, and district/
subdistrict hospitals, that were sampled in this analysis
(Table 1, Online Fig. 1). Most health care sites were public-
sector facilities, followed by private-sector and faith-based
organization facilities. At baseline, intervention and con-
trol facilities did not differ substantially. A significantly
greater proportion of intervention facilities had access to
electricity and piped water (p < 0.05 for both); however,
access to basic health care equipment, including BP ma-
chines, did not differ significantly between groups
(Table 1). At baseline, staff composition was fairly similar
at intervention and control facilities. However, after
12 months, both groups reported a significant increase in
registered nurses and clinical officers (p < 0.01) (see
Online Table 1, which displays the staffing of facilities).
HCPs’ knowledge of hypertension
Over 12 months, the HHA program improved HCPs’
knowledge of risk factors for hypertension and methods for
reducing or managing hypertension (Table 2; Online
Table 2). A significantly greater proportion of HCPs from
intervention versus control facilities identified tobacco use
(p < 0.01) and alcohol consumption (p < 0.05) as risk
factors for hypertension (Table 2). The proportion of HCPs
who identified at least 5 risk factors for hypertension
increased significantly at intervention facilities, an estimated
treatment effect of 21.2 percentage points (pp) (p < 0.05)
(Table 2). The proportion of HCPs who recommended di-
etary changes to manage or reduce hypertension increased
by 25.6 pp (p< 0.05) at intervention facilities (Table 2). The
proportion of HCPs from intervention facilities who iden-
tified at least 5 methods for reducing or managing hyper-
tension increased by 43.6 pp (p < 0.05) (Table 2). At both
intervention and control facilities, the proportion of HCPs
who identified the correct BP thresholds increased from
baseline to end line (Table 2). The HHA program did not
have a positive effect on HCP’s knowledge of hypertension
consequences (Table 2).
Hypertension services
At end line, a greater proportion of intervention versus
control facilities was likely to repeat BP measurements at
the same visit to diagnose hypertension (estimated treat-
ment effect, 29.3 pp; p < 0.05), have days dedicated to
hypertension care (22.5 pp; p < 0.05), and display posters
to increase awareness of hypertension (49.3 pp; p < 0.01)
and BP thresholds (28.0 pp; p < 0.01) (Table 3). The
availability of hypertension medications improved at
intervention facilities, with availability of guideline-
recommended drugs such as hydrochlorothiazide and
amlodipine increasing by 25.4 pp (p < 0.05) and 17.0 pp
(p ¼ not significant), respectively, relative to control fa-
cilities, whereas availability of b-blockers or methyldopa
(not guideline-recommended drugs) remained mostly un-
changed (Table 3). The number of new patients with hy-
pertension within the last 3 months and those seeking
treatment (returning to the facility for BP checks and/or to
receive medication) numerically increased at both inter-
vention and control facilities (Fig. 2; Online Table 3).
Monitoring data (captured by implementing partners, not
the facility survey) demonstrated an increasing trend in the
number of patients screened, diagnosed, and treated for
hypertension (Fig. 3).
TABLE 1. Facility characteristics at baseline
Facility Characteristics, %
Intervention
(n ¼ 66)
Control
(n ¼ 66) p Value
Sector 0.998
Public 44.6 45.1
Private 36.2 35.7
Faith-based 19.2 19.2
Health care level 0.373
Dispensary/clinic 55.9 67.2
Health center 24.0 20.8
District/subdistrict hospital 20.1 12.1
Facility location 0.328
Urban 46.5 36.6
Rural 53.5 63.4
Infrastructure
Electricity 96.3 85.8 0.041
Piped water 88.5 68.7 0.008
Equipment
Stethoscope 96.9 97.2 0.932
Blood pressure machine 99.2 93.3 0.093
Adult weighing scale 95.2 92.7 0.558
Thermometer 98.8 94.7 0.200
Measuring tape 84.8 81.2 0.613
Stadiometer 27.4 30.8 0.690
Provider type
Physician 9.6 7.7 0.706
Medical officer 13.7 15.8 0.768
Clinical officer 32.2 35.9 0.693
Degree nurse 15.8 10.3 0.365
Registered nurse 61.8 44.0 0.071
Registered midwife 34.2 20.5 0.117
Enrolled nurse 55.3 41.7 0.165
Nurse attendant 20.0 12.4 0.312
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TABLE 2. HCPs’ knowledge of HTN-related risk factors and consequences, BP thresholds, and methods for reducing HTN
Baseline End Line
Treatment Effect (SE),
Percentage Points
Intervention
(n ¼ 66)
Control
(n ¼ 66)
Intervention
(n ¼ 66)
Control
(n ¼ 66)
HCPs who identified, %
3 HTN risk factors 38.5 54.0 68.6 69.6 16.8 (12.7)
5 HTN risk factors 9.7 6.1 30.7 7.9 21.2 (9.4)*
3 medically known
consequences of HTN
79.5 76.6 59.7 68.8 9.3 (12.9)
5 medically known
consequences of HTN
24.2 23.8 14.4 19.2 4.4 (11.0)
3 medically known
methods for reducing/
managing HTN
66.7 67.7 80.9 81.8 0.1 (11.7)
5 medically known
methods for reducing/
managing HTN
15.4 33.0 49.8 27.1 43.6 (11.2)*
Systolic and diastolic
thresholds for high BP
49.7 38.6 87.7 91.1 12.3 (10.2)
Systolic and diastolic
thresholds for severe high
BP
12.4 8.9 74.2 66.5 7.2 (10.1)
HCPs who identified risk factors
of HTN, %
Age 30.8 24.5 34.2 37.0 6.7 (12.0)
Family history 62.9 59.9 69.7 64.0 0.2 (12.4)
High BMI/obesity/overweight 39.1 42.5 80.1 67.8 15.1 (11.3)
High salt intake 37.1 36.7 36.8 48.1 10.4 (13.1)
Use of tobacco products 33.9 34.6 58.1 26.8 34.4 (12.6)y
High alcohol consumption 21.3 39.1 48.1 37.5 30.4 (12.7)*
Lack of physical activity 41.7 41.8 27.3 35.5 9.1 (12.7)
HCPs who identified
consequences of HTN, %
Death 41.6 50.3 41.0 54.0 0.1 (12.2)
Heart attack 52.8 47.3 45.8 49.4 5.0 (13.4)
Stroke 88.3 77.4 87.8 90.4 10.9 (9.2)
Aneurysm 16.1 17.0 15.5 15.3 0.7 (9.0)
Heart failure 67.6 44.3 47.6 67.3 43.0 (14.1)y
Loss of sight 38.2 38.5 43.2 21.7 22.0 (11.9)
Renal disease 42.7 39.6 4.5 7.3 6.3 (12.8)
HCPs who identified methods
for reducing/managing HTN,
%
Reduce salt 43.3 47.5 51.1 47.7 6.7 (13.4)
Weight loss 32.2 45.8 44.0 56.4 9.4 (9.9)
Medication 54.3 74.5 54.5 61.7 12.6 (13.8)
Exercise 79.3 68.7 80.0 68.5 3.1 (12.2)
Dietary changes 48.6 49.9 69.8 49.6 25.6 (12.8)*
Reduce alcohol 35.1 33.9 56.9 36.0 22.8 (12.5)
Stop smoking 33.9 25.3 54.8 32.3 16.5 (12.4)
BMI, body mass index; BP, blood pressure; HCP, health care provider; HTN, hypertension; SE, standard error.
*p < 0.05.
yp < 0.01 vs. Intervention and Control facilities.
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DISCUSSION
This assessment of the HHA program provided data on the
status of hypertension care in Kenya, identified areas for
potential improvement, and provided a systematic review
of changes in these parameters over the 12-month study
period. Before implementation of the HHA program in
Kenya, hypertension treatment and control—especially in
primary health care facilities—were poor, with rates as low
as 9% and 3%, respectively [9]. Indeed, baseline data from
this study suggest that HCPs’ knowledge of high and
severely high BP thresholds, hypertension-associated risk
factors, consequences, and services, including access to
medication, was poor among the participating facilities,
presumably because of low rates of hypertension screening
and treatment at primary care facilities. After 12 months of
implementation, early evidence demonstrated the positive
impact of the HHA program in addressing some of these
barriers to hypertension care.
The interventions implemented as part of the HHA
program increased the emphasis on hypertension preven-
tative care, screening, diagnosis, and treatment at partici-
pating facilities. The observed increase in the identification
of influential risk factors for hypertension by HCPs sup-
ports the effectiveness of this approach. An increase in the
proportion of HCPs able to identify dietary changes,
reduction of alcohol use, and cessation of smoking as
methods for reducing hypertension was also observed from
the beginning to the end of the study period. This may lead
to increased patient education and, in turn, to adoption of
positive lifestyle modifications. Moderation of alcohol
intake and improvements in nutrition (increased con-
sumption of fruit and vegetables; reduced fat and sodium
intake) can reduce systolic BP by w2 to 4 mm Hg and w2
to 14 mm Hg, respectively [13].
More frequent BP monitoring and greater understand-
ing of the measured values were also documented. HCPs
were observed to measure BP more than once in the same
visit at intervention facilities, an activity that is expected to
result inmore accurate diagnosis of high BP among Kenyans.
Amarked increase in the proportion of HCPswho accurately
provided correct systolic and diastolic BP thresholds was
observed at both intervention and control facilities. How-
ever, because the change from baseline to end line was
greater for the control (from 38.6% to 91.1%) versus
intervention (from 49.7% to 87.7%) facilities, the HHA
program did not appear to have a positive effect. The
observed increase among the control facilities was unex-
pected and may be attributed to a scale-up of activities that
were launched in response to the national and global ini-
tiatives to improve noncommunicable disease control
[5,14]. Even though it is assumed that HCPs received pre-
vious training in hypertension care, the current data indicate
TABLE 3. Hypertension services offered
Baseline End Line
Treatment Effect (SE),
Percentage Points
Intervention
(n ¼ 66)
Control
(n ¼ 66)
Intervention
(n ¼ 66)
Control
(n ¼ 66)
HCPs who measured, %
BP every visit 88.6 86.9 98.0 90.0 5.3 (7.5)
BP >1 time to diagnose HTN 71.0 79.5 84.7 65.0 29.3 (12.0)*
Facilities with, %
Dedicated days to HTN care 28.8 14.8 54.4 15.1 22.5 (10.4)*
Displayed educational HTN posters 10.8 3.0 79.5 19.7 49.3 (9.3)y
Displayed BP threshold 6.2 5.3 44.2 13.4 28.0 (9.2)y
Available medications,z %
Thiazides
Hydrochlorothiazide 46.3 51.6 64.3 45.6 25.4 (11.2)*
Calcium channel blockers
Amlodipine 26.7 15.5 44.9 15.0 17.0 (9.7)
Nifedipine 65.0 52.8 73.3 51.6 11.1 (12.0)
b-blockers
Propranolol 32.9 9.0 29.7 13.4 4.3 (7.8)
ACE inhibitors
Enalapril 47.1 32.6 56.3 27.9 15.0 (10.3)
Centrally acting drugs
Methyldopa 38.4 29.3 38.5 28.9 1.7 (10.3)
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; other abbreviations as in Table 2.
*p < 0.05.
yp < 0.01 vs. Intervention and Control facilities.
zAvailability of medication defined based on visual confirmation that the facility had the medication in stock.
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the need for continuous reinforcement, through further
medical training (including program retraining) and clinical
practices, to motivate HCPs to engage in hypertension care
on a more regular basis. The indication of activities for
noncommunicable diseases (including hypertension) con-
trol supports the growing interest in hypertension care in
Kenya and further demonstrates that these HCPs are
receptive to improvements in their practices and striving to
provide better patient care.
Although this 12-month pilot study demonstrates the
positive impact of the HHA program on HCPs’ knowledge
of hypertension and standard of care, there is room for
further improvement. Because the HHA-developed proto-
col did not stress the consequences of untreated hyper-
tension, the HHA program did not affect HCPs’ knowledge
of hypertension-related consequences over the 12-month
observation period. Although it is possible that an
improvement in knowledge may be observed over a longer
period of time, these data demonstrate that specific edu-
cation on hypertension-related consequences should be
included in the HHA program, as this knowledge provides
the rationale for screening, diagnosing, and treating hy-
pertension for both HCPs and community members.
The HHA program had a positive impact on the avail-
ability of hypertension medications, particularly thiazides
and calcium channel blockers, which were emphasized in
the HHA hypertension protocol. In particular, availability of
hydrochlorothiazide and amlodipine increased after the
12-month period. Although this evaluation did not study
the facilities’ access to medications in great detail, the lack of
significant improvement in access to protocol-
recommended medications among intervention facilities
may be attributed to the differences in procurement pro-
cesses between implementing partners and among public
versus private health care facilities. During the first year of
the HHA program, no increase was noted in the average
number of patients diagnosed with hypertension or the
number of patients returning for care. Because the facility
survey did not capture the number of patients screened for
hypertension, several scenarios are possible. Screening rates
may have been low, or the patients screened may have been
healthy or sought care elsewhere if they were hypertensive.
Alternatively, increases in hypertension diagnosis and
adherence to hypertension care may be long-term outcomes
and not achievable by an educational program in 1 year.
Nonetheless, the monitoring data demonstrated a trend to-
ward increased screening, diagnosis, and treatment for hy-
pertension, indicating that continuing the program may
result in clear benefits over time.
Similar studies have shown that improving HCP edu-
cation can translate into improvements in BP control over
time. Training rural Vietnamese health care workers in
proper hypertension management led to a significant
reduction in systolic and diastolic BP among 459 patients
within 17 months [11]. Similarly, a 10-month program
that focused on training pharmacists in Nigeria to take
patients’ BP and counsel 40 hypertensive patients led to a
decrease in average systolic and diastolic BP and
improvement in healthy lifestyle activities, such as
reducing salt intake, alcohol moderation, and exercise [12].
Treatment Effect = 4.14
0
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FIGURE 2. Differences-in-differences graphs describing
the impact of Healthy Heart Africa on the number of hy-
pertension (HTN) cases. (A) No. of HTN patients within the
last 3 months; (B) Number of new HTN patients within the
last 3 months; (C) Number of new HTN patients receiving
BP checks and medication on a monthly basis.
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The Kenyan health care system is continuously
evolving because of the recent devolution of Kenya’s
centralized governing system into 47 county governments
[13]. Whereas general improvements in hypertension care,
such as implementation of other training programs, are
positive for the community, capturing the full impact of the
HHA program can be challenging. In particular, program
evaluation may be impacted by the movement of medical
personnel, a by-product of the devolution, which occurred
across public facilities at the time of the study. The po-
tential exchange of HHA-trained HCPs for those from
control or nonparticipating facilities may contribute to
either a reduction or no change in knowledge with inter-
vention, as reflected by the lack of improvement in key
parameters, such as HCPs’ knowledge of high salt intake as
a hypertension risk factor and the use of medications for
the management of hypertension. This, in turn, may result
in smaller differences in knowledge between the treatment
groups and an underestimation of program impact. How-
ever, a major strength of the current analysis was the use of
the differences-in-differences approach, which allows for
changes in underlying conditions over time when evalu-
ating the impact of the HHA program. Thus, this analysis
provided a high-quality snapshot of the positive impact of
HHA on hypertension care in Kenya during its first
12 months of implementation, despite changes in the
Kenyan health care system implemented during the study
period.
Within 12 months of implementation, HHA was
shown to have an initial positive impact on HCP knowl-
edge. However, the evaluation period was not sufficient to
realize the full impact of the program on the hypertension
care and services provided by both HCPs and facilities.
Significant changes in both behavior (e.g., HCPs’
knowledge and care) and at the system level (e.g., facilities
services and access to medications) are expected to occur
gradually over a prolonged period of time, typically several
years. Thus, a longer program evaluation period
(>12 months) is needed to identify key program attributes
that contribute to and/or are obstacles to achieving signif-
icant improvement in long-term hypertension care.
This analysis has additional limitations. The distribu-
tion of amenities (e.g., piped water and electricity) and
medical personnel (e.g., the proportion of clinical officers
or registered nurses) was not equal between intervention
and control facilities because it was not possible to match
all intervention facilities with a perfectly comparable con-
trol facility. In particular, implementation facilities tended
to be in urban areas, which likely explains the differences
in amenities and staffing. However, matching facilities
based on key characteristics reduced the potential for bias.
The modest sample size limits the ability to make any
comparisons based on geographic location and facility
sectors. At times, HCPs may have misunderstood survey
questions, possibly resulting in the decreased responses to
certain questions over time. To minimize this possibility,
the survey questions were tested before fielding and
administered by medically trained personnel. Because the
primary focus of this pilot study was to evaluate the initial
impact of the HHA program on HCP’s knowledge of hy-
pertension, the study did not investigate in great detail
facility readiness (e.g., human resources, BP machines
[type, validity, and functionality], and procurement of
essential medicines) as well as the quality of the interven-
tion materials provided, including HCP training, as
compared with the World Health Organization tools, such
as the Service Availability and Readiness Assessment and
Package of Essential Noncommunicable Disease
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Interventions for primary health care in low-resource set-
tings [15,16]. Future evaluations of the HHA program will
utilize such tools to ensure that HCPs have the resources
and adequate training needed to provide high-quality care
and capture information regarding procurement of key
medications and training provided to HCPs.
CONCLUSIONS
Overall, the HHA program positively affected HCPs’
knowledge and practice of hypertension care at 12 months
and supported the public-private partnership approach to
expand access to care across a diverse population, differ-
entiated by health care sources. Through collaboration
with the Kenyan Ministry of Health and leading imple-
mentation partners, HHA was able to utilize the existing
health care infrastructure to expand the outreach of HHA
for providing improved care for people in Kenya. HHA
improved HCP training and the quality of hypertension
services by integrating hypertension services into primary
and community health care systems, which largely focus
on maternal/child health, human immunodeficiency virus,
and malaria. The HHA program contributes to the Kenyan
government’s ongoing efforts to achieve the World Health
Organization’s goal of reducing the prevalence of raised BP
by 25% by 2025 and is also in line with the World Heart
Federation and the Pan-African Society of Cardiology
roadmaps for achieving hypertension control [14].
The development and dissemination of uniform hy-
pertension management protocols, efficient supply and
distribution of hypertension medications, and other ini-
tiatives to improve hypertension care in primary care set-
tings are important throughout the region. Future scale-up
efforts across Kenya, Ethiopia, and sub-Saharan Africa will
focus on developing effective strategies for improving hy-
pertension detection/diagnosis, HCP knowledge and
treatment practices, and access to essential medications.
The lessons learned from HHA will help to inform ongoing
efforts to improve hypertension care in primary health care
settings and the development of health care policy and
infrastructure across Africa. Through new collaborative
partnerships, the HHA program hopes to expand access to
and uptake of care for chronic conditions in under-
resourced settings.
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